It appears that your browser may be outdated and performance may be limited. The My Study builder is best viewed with the latest internet browsers. However, if you’d prefer to use our standard form, you can access it below.

Go to Internet Explorer Quick Quote Form

Dismiss this message

Salivary 17 Alpha-OHP ELISA Kit

Technical Summary

Assay Protocol
Rev. 02.26.16
Specifications
Catalog#: 1-2602
Format: 96-well plate
Assay Time: ~ 3 hrs
Sample Volume/Test: 50 µL
Sensitivity: 3 pg/mL
Assay Range: 5.1 pg/mL - 500pg/mL
Storage Requirements: 2-8°C
Tests Per Kit
Singlet: 76
Duplicate: 38
Target Analyte
Technical Documentation

Salivary 17 Alpha-Hydroxyprogesterone Assay Kit Overview

Intended Use

The Salimetrics 17 α-Hydroxyprogesterone (17-OH Progesterone) Enzyme Immunoassay Kit is a competitive immunoassay specifically designed and validated for the quantitative measurement of salivary 17-OH Progesterone. It is not intended for diagnostic use. It is intended only for research use in humans and some animals. Salimetrics has not validated this kit for serum or plasma samples.

Introduction

17-OH Progesterone (17-hydroxy-4-pregnene-3,20-dione) is a steroid hormone produced in the adrenal glands and the gonads. Immediate precursors are progesterone or 17- hydroxypregnenolone. In the human adrenal gland, 17-OH Progesterone is metabolized to 11- deoxycortisol, which is then further converted to the main end product cortisol. Production and conversion of 17-OH Progesterone are therefore essential to normal adrenal function. 17-OH Progesterone also serves as a precursor to the androgens and the estrogens, with androstenedione serving as the intermediary metabolite. The enzymatic activity that converts 17-OH Progesterone into androstenedione varies considerably according to species, however in the human adrenal gland, testis, and ovary, 17-OH Progesterone conversion to androstenedione is inefficient, and DHEA instead serves as the main precursor to androstenedione. 17-OH Progesterone produced in the human gonadal tissues is therefore largely an end product that enters the circulation, and, in the absence of adrenal dysfunction, circulating 17-OH Progesterone levels reflect gonadal rather than adrenal production. 17-OH Progesterone levels correlate with the changes in circulating estrogen levels seen during the follicular and luteal phases of the menstrual cycle in women. 17-OH Progesterone levels follow a circadian rhythm similar to that of cortisol, with highest values in the morning and a nadir in the evening. 17-OH Progesterone levels in humans are high at birth and drop rapidly over the first few days of life; they continue to decline more slowly over the first year. Levels remain low until they rise again during puberty. To ensure the most accurate results, this salivary immunoassay is designed using a matrix that matches saliva. The level of 17-OH Progesterone in saliva (pg/mL) is significantly lower than levels in the general circulation (ng/mL). The standard curve range is sensitive enough to capture individual differences in the 17-OH Progesterone levels expected in saliva. The current protocol uses only 50 µL of saliva per test. No separation or extractions are necessary.

17-OH Progesterone Assay Principle

This is a competitive immunoassay kit. 17-OH Progesterone in standards and samples compete with 17-OH Progesterone conjugated to horseradish peroxidase for the antibody binding sites on a microtitre plate. After incubation, unbound components are washed away. Bound 17-OH Progesterone Enzyme Conjugate is measured by the reaction of the horseradish peroxidase enzyme to the substrate tetramethylbenzidine (TMB). This reaction produces a blue color. A yellow color is formed after stopping the reaction with an acidic solution. The optical density is read on a standard plate reader at 450 nm. The amount of 17-OH Progesterone Enzyme Conjugate detected is inversely proportional to the amount of 17-OH Progesterone present in the sample.

References & Salivary 17-Alpha OHP Research

  1. Pasquali, R., Patton, L., Pocognoli, P., et al. (2007).  17-Hydroxyprogesterone responses to gonadotropin-releasing hormone disclose distinct phenotypes of functional ovarian hyperandrogenism and polycystic ovary syndrome.  J Clin Endocrin Metab, 92(11), 4208-17.
  2. Şahin, Y., Keleştimur, F. (1997). 17-Hydroxyprogesterone responses to gonadotrophin-releasing hormone agonist buserelin and adrenocorticotrophin in polycystic ovary syndrome: Investigation of adrenal and ovarian cytochrome P450c17α dysregulation.  Hum Reprod, 12(5), 910-13.
  3. Strott, C.A., Yoshimi, T., Lipsett, M.B. (1969).  Plasma progesterone and 17-hydroxyprogesterone in normal men and children with congenital adrenal hyperplasia.  J Clin Invest, 48(5), 930-39.
  4. Weliky, I., Engel, L.L. (1962).  Metabolism of progesterone-4-C14 and pregnenolone-7α-H3 by human adrenal tissue.  J Biol Chem, 238(4), 1302-7.
  5. Santos, C.M., Abad, L.R., Cua, S.C. & Domingo, C.F. (2003). Monitoring congenital adrenal hyperplasia using blood spot 17-hydroxyprogesterone assay. Southeast Asian J Trop Med Public Health, 34(Suppl 3), 174-8.
  6. Sack, J., Front, H., Kaiserman, I., Schreiber, M. (1997). 21-hydroxylase deficiency: Screening and incidence in Israel. Horm Res, 48(3), 115-9.
  7. New, M.I., Levine, L.S. (1984). Congenital adrenal hyperplasia. Monographs on Endocrinology, 26, 1-88.
  8. Van der Kamp, H.J, Wit, J.M. (2004). Neonatal screening for congenital adrenal hyperplasia. Eur J Endocrinol, 151(Suppl. 3), U71-5.
  9. Hughes, I.A., Winter, J.S. (1976).  The application of a serum 17-OH progesterone radioimmunoassay to the diagnosis and management of congenital adrenal hyperplasia. J Pediatrics, 88(5), 766-73.
  10. Gröschl, M., Rauh, M., Dörr, H.-G. (2003).  Circadian rhythm of salivary cortisol, 17α-hydroxyprogesterone, and progesterone in healthy children.  Clin Chem, 49(10), 1688-91.
  11. Goudas, V.T., Dumesic, D.A. (1997). Polycystic ovary syndrome. Endocrinol Metab Clin North Am, 26(4), 893-912.
  12. Vining, R.F., McGinley, R.A. (1987). The measurement of hormones in saliva: Possibilities and pitfalls. J Ster Biochem, 27(1-3), 81-94.